CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 102 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,717 | -14.2% | 294 | +2.8% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 286 | +61.6% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 177 | +13.5% | 0.00% | – |
| Q1 2022 | $1,000 | – | 156 | +0.6% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 155 | -99.5% | 0.00% | – |
| Q3 2021 | $99,000 | -22.7% | 30,305 | -0.5% | 0.00% | – |
| Q2 2021 | $128,000 | -57.0% | 30,448 | -48.9% | 0.00% | – |
| Q1 2021 | $298,000 | -67.4% | 59,578 | -17.7% | 0.00% | – |
| Q4 2020 | $915,000 | +125.4% | 72,400 | +75.1% | 0.00% | – |
| Q3 2020 | $406,000 | -42.0% | 41,355 | -41.1% | 0.00% | – |
| Q2 2020 | $700,000 | +68.7% | 70,270 | +49.7% | 0.00% | – |
| Q1 2020 | $415,000 | +68.7% | 46,925 | +76.2% | 0.00% | – |
| Q4 2019 | $246,000 | -18.0% | 26,629 | -47.9% | 0.00% | – |
| Q3 2019 | $300,000 | -52.4% | 51,139 | -2.7% | 0.00% | – |
| Q2 2019 | $630,000 | +26.0% | 52,544 | +26.7% | 0.00% | – |
| Q1 2019 | $500,000 | -54.4% | 41,481 | -52.5% | 0.00% | – |
| Q4 2018 | $1,096,000 | -14.3% | 87,331 | +1.3% | 0.00% | – |
| Q3 2018 | $1,279,000 | +4.2% | 86,243 | +18.2% | 0.00% | – |
| Q2 2018 | $1,228,000 | +73.0% | 72,939 | +134.8% | 0.00% | – |
| Q1 2018 | $710,000 | -72.0% | 31,062 | -68.3% | 0.00% | -100.0% |
| Q4 2017 | $2,533,000 | +1089.2% | 97,870 | +575.8% | 0.00% | – |
| Q3 2017 | $213,000 | +15.1% | 14,482 | +9.3% | 0.00% | – |
| Q2 2017 | $185,000 | -60.8% | 13,254 | -52.2% | 0.00% | – |
| Q1 2017 | $472,000 | +17.1% | 27,728 | -29.3% | 0.00% | – |
| Q4 2016 | $403,000 | +24.4% | 39,226 | +22.1% | 0.00% | – |
| Q3 2016 | $324,000 | -9.7% | 32,135 | +0.4% | 0.00% | – |
| Q2 2016 | $359,000 | -22.3% | 31,999 | -5.4% | 0.00% | – |
| Q1 2016 | $462,000 | +183.4% | 33,811 | +293.4% | 0.00% | – |
| Q4 2015 | $163,000 | +150.8% | 8,595 | +147.4% | 0.00% | – |
| Q3 2015 | $65,000 | -49.6% | 3,474 | -59.9% | 0.00% | – |
| Q2 2015 | $129,000 | -82.3% | 8,670 | -82.0% | 0.00% | – |
| Q1 2015 | $730,000 | +61.9% | 48,094 | +42.0% | 0.00% | – |
| Q4 2014 | $451,000 | +160.7% | 33,873 | +147.2% | 0.00% | – |
| Q3 2014 | $173,000 | +32.1% | 13,700 | +5.8% | 0.00% | – |
| Q2 2014 | $131,000 | +142.6% | 12,950 | +221.3% | 0.00% | – |
| Q1 2014 | $54,000 | – | 4,030 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,420,349 | $25,814,838 | 3.96% |
| Parkman Healthcare Partners LLC | 1,203,484 | $7,028,347 | 1.87% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,002,783 | $5,856,253 | 1.26% |
| TANG CAPITAL MANAGEMENT LLC | 1,150,000 | $6,716,000 | 0.98% |
| BVF INC/IL | 3,629,000 | $21,193,360 | 0.89% |
| Nantahala Capital Management | 1,732,388 | $10,117,146 | 0.66% |
| AWM Investment Company, Inc. | 666,661 | $3,893,300 | 0.56% |
| INGALLS & SNYDER LLC | 1,295,833 | $7,568 | 0.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 200,800 | $1,172,672 | 0.36% |
| Kensington Investment Counsel, LLC | 58,599 | $342,218 | 0.27% |